The European Medicines Agency’s CHMP has issued a positive opinion for the approval of Olumiant (baricitinib) for adolescents aged 12 to 18 suffering from severe alopecia areata (AA). This Janus kinase (JAK) inhibitor was originally discovered by Incyte and licensed to Eli Lilly.
Clinical Efficacy and Medical Significance The recommendation is backed by 36-week data from the Phase III BRAVE-AA-PEDS study. Key findings include:
-
A significant number of adolescent patients achieved near-complete scalp hair regrowth.
-
Successful regrowth was also observed in patients who had experienced eyebrow and eyelash loss.
[Image: Diagram of an oral tablet for the treatment of autoimmune hair loss]
Psychological and Social Impact Alopecia areata is an autoimmune condition where the body attacks its own hair follicles. For adolescents, the impact goes beyond physical appearance, often affecting emotional well-being and social identity during a sensitive developmental stage. Dermatologists emphasize that this oral, once-daily treatment could provide a vital solution for a particularly vulnerable population.
Olumiant was previously approved for severe AA in adults by both the FDA and the European Commission in 2022. A final decision on the expanded pediatric label is expected from the European Commission within the next 60 days.